Mergers and Innovation in the Pharmaceutical Market

Frederic Michael Scherer and William S. Comanor

Scholarly Articles from Harvard Kennedy School of Government

Abstract: The U.S. pharmaceutical industry has experienced in recent years two dramatic changes: stagnation in the growth of new molecular entities approved for marketing, and a wave of mergers linking inter alia some of the largest companies. This paper explores possible links between these two phenomena and proposes alternative approach to merger policy. It points to the high degree of uncertainty encountered in the discovery and development of new pharmaceutical entities and shows how optimal strategies entail the pursue of parallel research and development paths. Uncertainties afflict both success rates and financial gains contingent upon success. A new model simulating optimal strategies given prevalent market uncertainties is presented. Parallelism can be sustained both within individual companies’ R&D programs and across competing companies. The paper points to data showing little parallelism of programs within companies and argues that inter-company mergers jeopardize desirable parallelism across companies.

Date: 2011
New Economics Papers: this item is included in nep-com, nep-hme, nep-ind and nep-ino
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Published in HKS Faculty Research Working Paper Series

Downloads: (external link)
http://dash.harvard.edu/bitstream/handle/1/5347067/RWP11-043_Scherer.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hrv:hksfac:5347067

Access Statistics for this paper

More papers in Scholarly Articles from Harvard Kennedy School of Government Contact information at EDIRC.
Bibliographic data for series maintained by Office for Scholarly Communication ().